Novel aspects on the contribution of T cells and dendritic cells in the pathogenesis of myositis

References

• Dalakas MC. Polymyositis, dermatomyositis and inclusion-body myositis. N Engl J Med 1991; 325: 1487–1498
   PubMed Web of Science ®Google Scholar
• Lundberg I, Chung Y. Treatment and investigation of idiopathic inflammatory myopathies. Rheumatology (Oxford) 2000; 39: 7–17
   PubMed Web of Science ®Google Scholar
• Dalakas MC. The molecular and cellular pathology of inflammatory muscle diseases. Curr Opin Pharmacol 2001; 1: 300–306
   PubMedGoogle Scholar
• Dalakas MC. Therapeutic approaches in patients with inflammatory myopathies. Semin Neurol 2003; 23: 199–206
   PubMedGoogle Scholar
• Targoff IN. Idiopathic inflammatory myopathy: Autoantibody update. Curr Rheumatol Rep 2002; 4: 434–441
   PubMedGoogle Scholar
• Howard OM, Dong HF, Yang D, Raben N, Nagaraju K, Rosen A, Casciola-Rosen L, Hartlein M, Kron M, Yiadom K, Dwivedi S, Plotz PH, Oppenheim JJ. Histidyl-tRNA synthetase and asparaginyl-tRNA synthetase, autoantigens in myositis, activate chemokine receptors on T lymphocytes and immature dendritic cells. J Exp Med 2002; 196: 781–791
   PubMed Web of Science ®Google Scholar
• Ytterberg SR. Infectious agents associated with myopathies. Curr Opin Rheumatol 1996; 8: 507–513
   PubMedGoogle Scholar
• Leff RL, Love LA, Miller FW, Greenberg SJ, Klein EA, Dalakas MC, Plotz PH. Viruses in idiopathic inflammatory myopathies: Absence of candidate viral genomes in muscle. Lancet 1992; 339: 1192–1195
   PubMed Web of Science ®Google Scholar
• Chevrel G, Calvet A, Belin V, Miossec P. Dermatomyositis associated with the presence of parvovirus B19 DNA in muscle. Rheumatology (Oxford) 2000; 39: 1037–1039
   PubMed Web of Science ®Google Scholar
• Chevrel G, Borsotti JP, Miossec P. Lack of evidence for a direct involvement of muscle infection by parvovirus B19 in the pathogenesis of inflammatory myopathies. A follow-up study. Rheumatology 2003; 42: 349–352
   PubMedGoogle Scholar
• Steinman RM. The dendritic cell system and its role in immunogenicity. Ann Rev Immunol 1991; 9: 271–296
   PubMed Web of Science ®Google Scholar
• Goebels N, Michaelis D, Wekerle H, Hohlfeld R. Human myoblasts as antigen-presenting cells. J Immunol 1992; 149: 661–667
   PubMedGoogle Scholar
• Curnow J, Corlett L, Willcox N, Vincent A. Presentation by myoblasts of an epitope from endogenous acetylcholine receptor indicates a potential role in the spreading of the immune response. J Neuroimmunol 2001; 115: 127–134
   PubMedGoogle Scholar
• Wiendl H, Lautwein A, Mitsdorffer M, Krause S, Erfurth S, Wienhold W, Morgalla M, Weber E, Overkleeft HS, Lochmuller H, Melms A, Tolosa E, Driessen C. Antigen processing and presentation in human muscle: Cathepsin S is critical for MHC class II expression and upregulated in inflammatory myopathies. J Neuroimmunol 2003; 138: 132–143
   PubMed Web of Science ®Google Scholar
• Banchereau J, Steinman RM. Dendritic cells and the control of immunity. Nature 1998; 392: 245–252
   PubMed Web of Science ®Google Scholar
• Pimorady-Esfahani A, Grounds MD, McMenamin PG. Macrophages and dendritic cells in normal and regenerating murine skeletal muscle. Muscle Nerve 1997; 20: 158–166
   PubMed Web of Science ®Google Scholar
• Thompson AG, Pettit AR, Padmanabha J, Mansfield H, Frazer IH, Strutton GM, Thomas R. Nuclear RelB+ cells are found in normal lymphoid organs and in peripheral tissue in the context of inflammation, but not under normal resting conditions. Immunol Cell Biol 2002; 80: 164–169
   PubMedGoogle Scholar
• Kawachi I, Tanaka K, Tanaka M, Tsuji S. Dendritic cells presenting pyruvate kinase M1/M2 isozyme peptide can induce experimental allergic myositis in BALB/c mice. J Neuroimmunol 2001; 117: 108–115
   PubMedGoogle Scholar
• Page G, Chevrel G, Miossec P. Anatomic localization of immature and mature dendritic cell subsets in dermatomyositis and polymyositis: Interaction with chemokines and Th1 cytokineyproducing cells. Arthritis Rheum 2004; 50: 199–208
   PubMedGoogle Scholar
• Caux C, Massacrier C, Vanbervliet B, Dubois B, de Saint-Vis B, Dezutter-Dambuyant C, Jacquet C, Schmitt D, Banchereau J. CD34+ hematopoietic progenitors from human cord blood differentiate along two independent dendritic cell pathways in response to GM-CSF+TNF alpha. Adv Exp Med Biol 1997; 417: 21–25
   PubMed Web of Science ®Google Scholar
• de Saint-Vis B, Vincent J, Vandenabeele S, Vanbervliet B, Pin JJ, Ait-Yahia S, Patel S, Mattei MG, Banchereau J, Zurawski S, Davoust J, Caux C, Lebecque S. A novel lysosome-associated membrane glycoprotein, DC-LAMP, induced upon DC maturation, is transiently expressed in MHC class II compartment. Immunity 1998; 9: 325–336
   PubMed Web of Science ®Google Scholar
• Zhou LJ, Tedder TF. Human blood dendritic cells selectively express CD83, a member of the immunoglobulin superfamily. J Immunol 1995; 154: 3821–3835
   PubMed Web of Science ®Google Scholar
• Arahata K, Engel AG. Monoclonal antibody analysis of mononuclear cells in myopathies. IV: Cell-mediated cytotoxicity and muscle fiber necrosis. Ann Neurol 1988; 23: 168–173
   PubMedGoogle Scholar
• Nyberg P, Wikman AL, Nennesmo I, Lundberg I. Increased expression of interleukin 1alpha and MHC class I in muscle tissue of patients with chronic, inactive polymyositis and dermatomyositis. J Rheumatol 2000; 27: 940–948
   PubMedGoogle Scholar
• Hohlfeld R, Engel AG. The immunobiology of muscle. Immunol Today 1994; 15: 269–274
   PubMedGoogle Scholar
• Hohlfeld R, Engel AG. Lysis of myotubes by alloreactive cytotoxic T cells and natural killer cells. Relevance to myoblast transplantation. J Clin Invest 1990; 86: 370–374
   PubMedGoogle Scholar
• Wiendl H, Mitsdoerffer M, Hofmeister V, Wischhusen J, Weiss EH, Dichgans J, Lochmuller H, Hohlfeld R, Melms A, Weller M. The non-classical MHC molecule HLA-G protects human muscle cells from immune-mediated lysis: Implications for myoblast transplantation and gene therapy. Brain 2003; 126: 176–185
   PubMed Web of Science ®Google Scholar
• Benveniste O, Cherin P, Maisonobe T, Merat R, Chosidow O, Mouthon L, Guillevin L, Flahault A, Burland MC, Klatzmann D, Herson S, Boyer O. Severe perturbations of the blood T cell repertoire in polymyositis, but not dermatomyositis patients. J Immunol 2001; 167: 3521–3529
   PubMed Web of Science ®Google Scholar
• Mantegazza R, Andreetta F, Bernasconi P, Baggi F, Oksenberg JR, Simoncini O, Mora M, Cornelio F, Steinman L. Analysis of T cell receptor repertoire of muscle-infiltrating T lymphocytes in polymyositis. Restricted V alpha/beta rearrangements may indicate antigen-driven selection. J Clin Invest 1993; 91: 2880–2886
   PubMed Web of Science ®Google Scholar
• O'Hanlon TP, Dalakas MC, Plotz PH, Miller FW. Predominant TCR-alpha beta variable and joining gene expression by muscle-infiltrating lymphocytes in the idiopathic inflammatory myopathies. J Immunol 1994; 152: 2569–2576
   PubMed Web of Science ®Google Scholar
• Nishio J, Suzuki M, Miyasaka N, Kohsaka H. Clonal biases of peripheral CD8 T cell repertoire directly reflect local inflammation in polymyositis. J Immunol 2001; 167: 4051–4058
   PubMedGoogle Scholar
• Choi YC, Dalakas MC. Expression of matrix metalloproteinases in the muscle of patients with inflammatory myopathies. Neurology 2000; 54: 65–71
   PubMed Web of Science ®Google Scholar
• Cherin P, Herson S, Crevon MC, Hauw JJ, Cervera P, Galanaud P, Emilie D. Mechanisms of lysis by activated cytotoxic cells expressing perforin and granzyme-B genes and the protein TIA-1 in muscle biopsies of myositis. J Rheumatol 1996; 23: 1135–1142
   PubMed Web of Science ®Google Scholar
• Lundberg I, Brengman JM, Engel AG. Analysis of cytokine expression in muscle in inflammatory myopathies, Duchenne dystrophy, and non-weak controls. J Neuroimmunol 1995; 63: 9–16
   PubMed Web of Science ®Google Scholar
• Tews DS, Goebel HH. Cytokine expression profile in idiopathic inflammatory myopathies. J Neuropathol Exp Neurol 1996; 55: 342–347
   PubMed Web of Science ®Google Scholar
• Lepidi H, Frances V, Figarella-Branger D, Bartoli C, Machado-Baeta A, Pellissier JF. Local expression of cytokines in idiopathic inflammatory myopathies. Neuropathol Appl Neurobiol 1998; 24: 73–79
   PubMed Web of Science ®Google Scholar
• Lundberg I, Ulfgren AK, Nyberg P, Andersson U, Klareskog L. Cytokine production in muscle tissue of patients with idiopathic inflammatory myopathies. Arthritis Rheum 1997; 40: 865–874
   PubMed Web of Science ®Google Scholar
• Confalonieri P, Bernasconi P, Megna P, Galbiati S, Cornelio F, Mantegazza R. Increased expression of beta-chemokines in muscle of patients with inflammatory myopathies. J Neuropathol Exp Neurol 2000; 59: 164–169
   PubMed Web of Science ®Google Scholar
• Adams EM, Kirkley J, Eidelman G, Dohlman J, Plotz PH. The predominance of beta (CC) chemokine transcripts in idiopathic inflammatory muscle diseases. Proc Assoc Am Physicians 1997; 109: 275–285
   PubMedGoogle Scholar
• Chevrel G, Page G, Granet C, Streichenberger N, Varennes A, Miossec P. Interleukin-17 increases the effects of IL-1 beta on muscle cells: Arguments for the role of T cells in the pathogenesis of myositis. J Neuroimmunol 2003; 137: 125–133
   PubMed Web of Science ®Google Scholar
• Jovanovic DV, Di Battista JA, Martel-Pelletier J, Jolicoeur FC, He Y, Zhang M, Mineau F, Pelletier JP. IL-17 stimulates the production and expression of proinflammatory cytokines. J Immunol 1998; 160: 3513–3521
   PubMed Web of Science ®Google Scholar
• Chabaud M, Fossiez F, Taupin JL, Miossec P. Enhancing effect of IL-17 on IL-1-induced IL-6 and leukemia inhibitory factor production by rheumatoid arthritis synoviocytes and its regulation by Th2 cytokines. J Immunol 1998; 161: 409–414
   PubMed Web of Science ®Google Scholar
• Leon-Monzon M, Dalakas M. Interleukin-1 (IL-1) is toxic to human muscle. Neurology 1994; 44: 132, suppl
   Google Scholar
• Kalovidouris AE, Plotkin Z. Synergistic cytotoxic effect of interferon-gamma and tumor necrosis factor-alpha on cultured human muscle cells. J Rheumatol 1995; 22: 1698–1703
   PubMed Web of Science ®Google Scholar
• Shelton GD, Calcutt NA, Garrett RS, Gu D, Sarvetnick N, Campana WM, Powell HC. Necrotizing myopathy induced by overexpression of IFN-g in transgenic mice. Muscle Nerve 1999; 22: 156–165
   PubMedGoogle Scholar
• Dieu MC, Vanbervliet B, Vicari A, Bridon JM, Oldham E, Ait-Yahia S, Briere F, Zlotnik A, Lebecque S, Caux C. Selective recruitment of immature and mature dendritic cells by distinct chemokines expressed in different anatomic sites. J Exp Med 1998; 188: 373–386
   PubMed Web of Science ®Google Scholar
• Wiendl H, Mitsdoerffer M, Schneider D, Melms A, Lochmuller H, Hohlfeld R, Weller M. Muscle fibres and cultured muscle cells express the B7.1/2-related inducible co-stimulatory molecule, ICOSL: Implications for the pathogenesis of inflammatory myopathies. Brain 2003; 126: 1026–1035
   PubMed Web of Science ®Google Scholar
• Ngo VN, Tang HL, Cyster JG. Epstein-Barr virus-induced molecule 1 ligand chemokine is expressed by dendritic cells in lymphoid tissues and strongly attracts naive T cells and activated B cells. J Exp Med 1998; 188: 181–191
   PubMed Web of Science ®Google Scholar
• Caux C, Massacrier C, Dubois B, Valladeau J, Dezutter-Dambuyant C, Durand I, Schmitt D, Saeland S. Respective involvement of TGF-beta and IL-4 in the development of Langerhans cells and non-Langerhans dendritic cells from CD34+ progenitors. J Leukoc Biol 1999; 66: 781–791
   PubMed Web of Science ®Google Scholar
• Maini RN, Breedveld FC, Kalden JR, Smolen JS, Davis D, Macfarlane JD, Antoni C, Leeb B, Elliott MJ, Woody JN, Schaible TF, Feldmann M. Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis. Arthritis Rheum 1998; 41: 1552–1563
   PubMed Web of Science ®Google Scholar
• Lipsky PE, van der Heijde DM, St Clair EW, Furst DE, Breedveld FC, Kalden JR, Smolen JS, Weisman M, Emery P, Feldmann M, Harriman GR, Maini RN. Infliximab and methotrexate in the treatment of rheumatoid arthritis. N Engl J Med 2000; 343: 1594–1602, Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group
   PubMed Web of Science ®Google Scholar
• Weinblatt ME, Keystone EC, Furst DE, Moreland LW, Weisman MH, Birbara CA, Teoh LA, Fischkoff SA, Chartash EK. Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: The ARMADA trial. Arthritis Rheum 2003; 48: 35–45
   PubMed Web of Science ®Google Scholar
• De Bleecker JL, Meire VI, Declercq W, Van Aken EH. Immunolocalization of tumor necrosis factor-alpha and its receptors in inflammatory myopathies. Neuromuscul Disord 1999; 9: 239–246
   PubMed Web of Science ®Google Scholar
• Kuru S, Inukai A, Liang Y, Doyu M, Takano A, Sobue G. Tumor necrosis factor-alpha expression in muscles of polymyositis and dermatomyositis. Acta Neuropathol (Berl) 2000; 99: 585–588
   PubMed Web of Science ®Google Scholar
• Kuru S, Inukai A, Kato T, Liang Y, Kimura S, Sobue G. Expression of tumor necrosis factor-alpha in regenerating muscle fibers in inflammatory and non-inflammatory myopathies. Acta Neuropathol (Berl) 2003; 105: 217–224
   PubMed Web of Science ®Google Scholar
• Chabaud M, Miossec P. The combination of tumor necrosis factor alpha blockade with interleukin-1 and interleukin-17 blockade is more effective for controlling synovial inflammation and bone resorption in an ex vivo model. Arthritis Rheum 2001; 44: 1293–1303
   PubMedGoogle Scholar
• Chabaud M, Page G, Miossec P. Enhancing effect of IL-1, IL-17, and TNF-alpha on macrophage inflammatory protein-3alpha production in rheumatoid arthritis: Regulation by soluble receptors and Th2 cytokines. J Immunol 2001; 167: 6015–6020
   PubMed Web of Science ®Google Scholar
• Lundberg I, Kratz AK, Alexanderson H, Patarroyo M. Decreased expression of interleukin-1alpha, interleukin-1beta, and cell adhesion molecules in muscle tissue following corticosteroid treatment in patients with polymyositis and dermatomyositis. Arthritis Rheum 2000; 43: 336–348
   PubMed Web of Science ®Google Scholar
• Ulfgren AK, Grundtman C, Borg K, Alexanderson H, Andersson U, Harris HE, Lundberg IE. Down-regulation of the aberrant expression of the inflammation mediator high mobility group box chromosomal protein 1 in muscle tissue of patients with polymyositis and dermatomyositis treated with corticosteroids. Arthritis Rheum 2004; 50: 1586–1594
   PubMed Web of Science ®Google Scholar
• Levine TD. Rituximab in the treatment of dermatomyositis: An open-label pilot study. Arthritis Rheum 2005; 52: 601–607
   PubMed Web of Science ®Google Scholar
• Chevrel G, Granet C, Miossec P. Contribution of TNF alpha and IL-1 beta to IL-6 production, NF-κB nuclear translocation and class I MHC expression in muscle cells: In vitro regulation with specific cytokine inhibitors. Ann Rheum Dis 2005; 1257–1262
   PubMedGoogle Scholar